drugset / Trial / NCT06237881
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
Phase 1/2
Active not recruiting
15 enrolled
M.D. Anderson Cancer Center
KSQ Therapeutics, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.
Timeline
- Start
- 2024-01-31
- Primary completion
- 2027-01-01
- Completion
- 2029-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KSQ-001EX | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 600000 iu/kg | Intravenous |